648 related articles for article (PubMed ID: 30111356)
21. Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia.
Sogorb-Esteve A; Nilsson J; Swift IJ; Heller C; Bocchetta M; Russell LL; Peakman G; Convery RS; van Swieten JC; Seelaar H; Borroni B; Galimberti D; Sanchez-Valle R; Laforce R; Moreno F; Synofzik M; Graff C; Masellis M; Tartaglia MC; Rowe JB; Vandenberghe R; Finger E; Tagliavini F; Santana I; Butler CR; Ducharme S; Gerhard A; Danek A; Levin J; Otto M; Sorbi S; Le Ber I; Pasquier F; Gobom J; Brinkmalm A; Blennow K; Zetterberg H; Rohrer JD;
Alzheimers Res Ther; 2022 Aug; 14(1):118. PubMed ID: 36045450
[TBL] [Abstract][Full Text] [Related]
22. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
23. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.
Piccio L; Deming Y; Del-Águila JL; Ghezzi L; Holtzman DM; Fagan AM; Fenoglio C; Galimberti D; Borroni B; Cruchaga C
Acta Neuropathol; 2016 Jun; 131(6):925-33. PubMed ID: 26754641
[TBL] [Abstract][Full Text] [Related]
24. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study.
Ma LZ; Tan L; Bi YL; Shen XN; Xu W; Ma YH; Li HQ; Dong Q; Yu JT
Mol Neurodegener; 2020 Apr; 15(1):25. PubMed ID: 32276587
[TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia.
Santangelo R; Coppi E; Ferrari L; Bernasconi MP; Pinto P; Passerini G; Comi G; Magnani G
J Alzheimers Dis; 2015; 43(4):1429-40. PubMed ID: 25201781
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia.
Wilke C; Gillardon F; Deuschle C; Hobert MA; Jansen IE; Metzger FG; Heutink P; Gasser T; Maetzler W; Blauwendraat C; Synofzik M
Neurodegener Dis; 2017; 17(2-3):83-88. PubMed ID: 27760429
[TBL] [Abstract][Full Text] [Related]
27. CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia.
Clarke MTM; Brinkmalm A; Foiani MS; Woollacott IOC; Heller C; Heslegrave A; Keshavan A; Fox NC; Schott JM; Warren JD; Blennow K; Zetterberg H; Rohrer JD
Alzheimers Res Ther; 2019 Dec; 11(1):105. PubMed ID: 31847891
[TBL] [Abstract][Full Text] [Related]
28.
Tsai RM; Bejanin A; Lesman-Segev O; LaJoie R; Visani A; Bourakova V; O'Neil JP; Janabi M; Baker S; Lee SE; Perry DC; Bajorek L; Karydas A; Spina S; Grinberg LT; Seeley WW; Ramos EM; Coppola G; Gorno-Tempini ML; Miller BL; Rosen HJ; Jagust W; Boxer AL; Rabinovici GD
Alzheimers Res Ther; 2019 Jan; 11(1):13. PubMed ID: 30704514
[TBL] [Abstract][Full Text] [Related]
29. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest.
Foiani MS; Cicognola C; Ermann N; Woollacott IOC; Heller C; Heslegrave AJ; Keshavan A; Paterson RW; Ye K; Kornhuber J; Fox NC; Schott JM; Warren JD; Lewczuk P; Zetterberg H; Blennow K; Höglund K; Rohrer JD
J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):740-746. PubMed ID: 30981993
[TBL] [Abstract][Full Text] [Related]
30. Thalamic atrophy in frontotemporal dementia - Not just a
Bocchetta M; Gordon E; Cardoso MJ; Modat M; Ourselin S; Warren JD; Rohrer JD
Neuroimage Clin; 2018; 18():675-681. PubMed ID: 29876259
[TBL] [Abstract][Full Text] [Related]
31. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.
Suárez-Calvet M; Kleinberger G; Araque Caballero MÁ; Brendel M; Rominger A; Alcolea D; Fortea J; Lleó A; Blesa R; Gispert JD; Sánchez-Valle R; Antonell A; Rami L; Molinuevo JL; Brosseron F; Traschütz A; Heneka MT; Struyfs H; Engelborghs S; Sleegers K; Van Broeckhoven C; Zetterberg H; Nellgård B; Blennow K; Crispin A; Ewers M; Haass C
EMBO Mol Med; 2016 May; 8(5):466-76. PubMed ID: 26941262
[TBL] [Abstract][Full Text] [Related]
32. Microglial Reactivity Correlates with Presynaptic Loss Independent of β-Amyloid and Tau.
Lan G; Chen X; Yang J; Sun P; Cai Y; Li A; Zhu Y; Liu Z; Ma S; Guo T;
Ann Neurol; 2024 May; 95(5):917-928. PubMed ID: 38356322
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
[TBL] [Abstract][Full Text] [Related]
34. Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity.
Borrego-Écija S; Pérez-Millan A; Antonell A; Fort-Aznar L; Kaya-Tilki E; León-Halcón A; Lladó A; Molina-Porcel L; Balasa M; Juncà-Parella J; Vitorica J; Venero JL; Deierborg T; Boza-Serrano A; Sánchez-Valle R
Alzheimers Dement; 2024 Mar; 20(3):1515-1526. PubMed ID: 38018380
[TBL] [Abstract][Full Text] [Related]
35. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
Lleó A; Irwin DJ; Illán-Gala I; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
JAMA Neurol; 2018 Jun; 75(6):738-745. PubMed ID: 29554190
[TBL] [Abstract][Full Text] [Related]
36. Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum.
Paciotti S; Wojdała AL; Bellomo G; Toja A; Chipi E; Piersma SR; Pham TV; Gaetani L; Jimenez CR; Parnetti L; Chiasserini D
Alzheimers Res Ther; 2023 Jul; 15(1):124. PubMed ID: 37454217
[TBL] [Abstract][Full Text] [Related]
37. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.
Rauchmann BS; Schneider-Axmann T; Alexopoulos P; Perneczky R;
Neurobiol Aging; 2019 Feb; 74():182-190. PubMed ID: 30458365
[TBL] [Abstract][Full Text] [Related]
38. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia.
Rohrer JD; Woollacott IO; Dick KM; Brotherhood E; Gordon E; Fellows A; Toombs J; Druyeh R; Cardoso MJ; Ourselin S; Nicholas JM; Norgren N; Mead S; Andreasson U; Blennow K; Schott JM; Fox NC; Warren JD; Zetterberg H
Neurology; 2016 Sep; 87(13):1329-36. PubMed ID: 27581216
[TBL] [Abstract][Full Text] [Related]
39. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease.
Ewers M; Franzmeier N; Suárez-Calvet M; Morenas-Rodriguez E; Caballero MAA; Kleinberger G; Piccio L; Cruchaga C; Deming Y; Dichgans M; Trojanowski JQ; Shaw LM; Weiner MW; Haass C;
Sci Transl Med; 2019 Aug; 11(507):. PubMed ID: 31462511
[TBL] [Abstract][Full Text] [Related]
40. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia.
Borroni B; Benussi A; Archetti S; Galimberti D; Parnetti L; Nacmias B; Sorbi S; Scarpini E; Padovani A
Amyotroph Lateral Scler Frontotemporal Degener; 2015 Mar; 16(1-2):86-91. PubMed ID: 25352065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
